I-Mab Announces $315 Million Commercialization Deal for Growth Hormone
November 10, 2021 at 04:59 AM EST
Shanghai I-Mab formed a $315 million collaboration with Hubei Jumpcan Pharma to commercialize its human growth hormone in China . Jumpcan, which will pay $35 million upfront, specializes in pediatric drugs. Earlier this year, I-Mab started a pivotal China Phase III trial of eftansomatropin alfa as a weekly treatment for pediatric growth hormone deficiency (PGHD). The two companies will split commercialization revenues 50/50, with I-Mab also receiving royalties on sales. Most China recombinant human growth hormone therapies require daily injections, which lowers patient compliance. More details... Stock Symbols: (NSDQ: IMAB) (SHA: 600566) Share this with colleagues: // //